Ophthalmology Therapeutics: Does current pipeline innovation hold the potential to affect the future ophthalmology market?

This Frontier Pharma: Ophthalmology Therapeutics assesses first-in-class innovation in the ophthalmology pipeline, highlighting key trends in the distribution of these products.

Pune, India - March 14, 2018 /MarketersMedia/ —

The pipeline is varied in terms of molecular targets and molecule types. Products acting on the immune system and neurotransmitter signaling are the most prevalent, but no single target dominates by any clear margin. There are a total of 194 first-in class pipeline products in development for ophthalmologic indications 38% of the 512 pipeline products for which there is a disclosed molecular target. Encompassing gene therapies, slowing of the visual cycle and antisense therapies, the pipeline appears robust and has huge potential to strengthen treatment options for ophthalmological disorders.

Access Report Details at: https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs

Reasons To Buy
• Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.
• Visualize the composition of the ophthalmological disorders market in terms of dominant molecule types and targets, and understand the current unmet needs and how they can be addressed. This knowledge allows a competitive understanding of gaps in the market.
• Analyze the ophthalmological disorders pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating ophthalmological disorders to overcome the overwhelming level of unmet need.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
• Identify commercial opportunities in the ophthalmological disorders deals landscape by analyzing trends in licensing and co-development deals, and a curated list of ophthalmological disorder therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Get this report at: https://www.themarketreports.com/report/buy-now/935550

In the past the ophthalmological disorders therapy area has suffered from a lack of full understanding of the pathophysiology and underlying mechanisms of the diseases. However, as this knowledge has improved vastly in recent years, potential targets have been identified for treatment. As well as the main disorders previously mentioned, there is also interest in developing treatments for indications such as allergic conjunctivitis and retinitis pigmentosa. The approval of a gene therapy for retinitis pigmentosa is indicative of this progress, and represents the first gene therapy approved for an inherited condition by the FDA.

Inquire for more details at: https://www.themarketreports.com/report/ask-your-query/935550

Contact Info:
Name: Shirish Gupta
Email: sales@themarketreports.com
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL: https://marketersmedia.com/ophthalmology-therapeutics-does-current-pipeline-innovation-hold-the-potential-to-affect-the-future-ophthalmology-market/314326

For more information, please visit https://www.themarketreports.com/report/frontier-pharma-ophthalmology-therapeutics-gene-therapies-and-first-in-class-targets-offer-novel-treatments-for-substantial-unmet-needs-in-a-pipeline-dominated-by-angiogenic-and-immune-signaling-drugs%20%20

Source: MarketersMedia

Release ID: 314326

Latest News

Pompeo: No end to NKorea sanctions until 'denuclearization'

Sep 23, 2018

NEW YORK — Top U.S. diplomat Mike Pompeo said Sunday that economic sanctions on North Korea won't be reduced until it completes "denuclearization" after leader Kim Jong Un offered to close the North's main nuclear site in exchange for U.S. concessions. Kim said last week at a summit with South Korea's president that he was willing to dismantle the Nyongbyon nuclear complex in the presence of outside inspectors if the U.S. takes unspecified "corresponding measures." He also promised to dismantle the North's main rocket launch site. That has helped revive U.S.-North Korea diplomacy that had failed to make headway since...

At UN, unrepentant Trump set to rattle foes, friends alike

Sep 23, 2018

BRIDGEWATER, N.J. — President Donald Trump is poised to redouble his commitment to "America First" on the most global of stages this week. In the sequel to his stormy U.N. debut, Trump will stress his dedication to the primacy of U.S. interests while competing with Western allies for an advantage on trade and shining a spotlight on the threat that he says Iran poses to the Middle East and beyond. One year after Trump stood at the rostrum of the U.N. General Assembly and derided North Korea's Kim Jong Un as "Rocket Man," the push to denuclearize the Korean Peninsula...

Meghan reveals 'something blue' she wore at royal wedding

Sep 23, 2018

LONDON — It's an old tradition that a bride should have something old, something new, something borrowed and something blue on her wedding day, and the Duchess of Sussex followed at least part of that when she married Prince Harry. The former Meghan Markle has revealed in a television documentary that she had a piece of blue fabric from the dress she wore on her first date with Harry sewn into her wedding dress. She made the comments while discussing the dress in a documentary about Queen Elizabeth II called "Queen of the World." She didn't say whether she also...

Dolce&Gabbana explore DNA with star-filled cast

Sep 23, 2018

MILAN — Milan designers are embracing women of all shapes, sizes and ages, even if the young, thin model prevailed during this week's previews for next spring and summer. Marni's runway included women of different sizes while Dolce & Gabbana continued their embrace of models in a range of ages and sizes for their DNA runway show on Sunday. Highlights from Sunday's show, the fifth day of previews of womenswear for next spring and summer: DOLCE & GABBANA PAY TRIBUTE TO HERITAGE Dolce & Gabbana retraced their DNA by bringing back some of their most famous models: Carla Bruni in...

As aid checks go out, farmers worry bailout won't be enough

Sep 23, 2018

WASHINGTON — Farmers across the United States will soon begin receiving government checks as part of a billion-dollar bailout to buoy growers experiencing financial strain from President Donald Trump's trade disputes with China. But even those poised for big payouts worry it won't be enough. And while support for Trump is near unwavering in the heartland, some growers say that with the November election nearing, such disappointing aid outcomes could potentially affect their vote. "It's pretty obvious that the rural agriculture communities helped elect this administration, but the way things are going I believe farmers are going to have to...

Search

Obserworld delivers the most accurate and up-to-date world news for the global audience with a thorough research and in-depth interviews. Discover the world through Obserworld.

Contact us: sales[at]obserworld.com